Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 30

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 30
---
 the number and price of the Underwriter Warrants and the shares of common stock underlying such Underwriter Warrants in the event of recapitalization, merger, stock split or other structural transaction, or a future financing undertaken by us.

#### Lock-Ups
Our officers and directors have agreed that, for a period of 90 days from the date of this prospectus, they will not, subject to certain exceptions, offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock without the prior written consent of Newbridge. Additionally, we have also agreed that, for a period of 90 days from the date of this prospectus, we will not, subject to certain exceptions, offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock without the prior written consent of Newbridge. Newbridge, in its sole discretion, may release any of the securities subject to these lock-up agreements at any time without notice.

#### Nasdaq Global Market Listing
Our common stock is listed on Nasdaq Global Market under the symbol “GANX.” There is no established trading market for the Pre-Funded Warrants or Common Warrants, and we do not expect a trading market to develop. We do not intend to list the Pre-Funded Warrants or Common Warrants on The Nasdaq Global Market or on any national securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the Pre-Funded Warrants and Common Warrants will be extremely limited.

<div align='center'>S-20</div>

TABLE OF CONTENTS

#### Expenses and Reimbursements
We estimate that our portion of the total expenses of this offering will be approximately $ , which includes the fees and expenses for which we have agreed to reimburse the underwriter, including the fees and disbursements of counsel for the underwriter, in connection with the offering in an amount not to exceed $75,000.00.

Price Stabilization, Short Positions and Penalty Bids

Until the distribution of securities in this offering is complete, SEC rules may limit the ability of the underwriter to bid for and purchase shares of our common stock. As an